These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35621725)

  • 1. The effectiveness and value of tirzepatide for type 2 diabetes mellitus.
    Nikitin D; Lin GA; Campbell JD; Hansen RN; Brouwer E; Chen Y; Herron-Smith S; Agboola F; Pearson SD
    J Manag Care Spec Pharm; 2022 Jun; 28(6):680-684. PubMed ID: 35621725
    [No Abstract]   [Full Text] [Related]  

  • 2. Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.
    Chiu N; Aggarwal R; Bhatt DL
    J Am Heart Assoc; 2022 Aug; 11(16):e026297. PubMed ID: 35929468
    [No Abstract]   [Full Text] [Related]  

  • 3. Tirzepatide for Patients With Type 2 Diabetes.
    Chipkin SR
    JAMA; 2022 Feb; 327(6):529-530. PubMed ID: 35133426
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
    Hartman ML; Sanyal AJ; Loomba R; Wilson JM; Nikooienejad A; Bray R; Karanikas CA; Duffin KL; Robins DA; Haupt A
    Diabetes Care; 2020 Jun; 43(6):1352-1355. PubMed ID: 32291277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.
    Patoulias D; Doumas M; Papadopoulos C
    Am J Cardiol; 2022 Jun; 173():157-158. PubMed ID: 35459459
    [No Abstract]   [Full Text] [Related]  

  • 6. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
    Santulli G
    N Engl J Med; 2022 Feb; 386(7):e17. PubMed ID: 35172066
    [No Abstract]   [Full Text] [Related]  

  • 8. The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
    Papachristou S; Popovic DS; Papanas N
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3503. PubMed ID: 34626443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lilly's tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics.
    Mullard A
    Nat Rev Drug Discov; 2022 Jul; 21(7):480. PubMed ID: 35596075
    [No Abstract]   [Full Text] [Related]  

  • 10. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirzepatide: a new low for bodyweight and blood glucose.
    Bailey CJ
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):646-648. PubMed ID: 34419226
    [No Abstract]   [Full Text] [Related]  

  • 13. In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
    Davidson MB
    Ann Intern Med; 2022 Oct; 175(10):JC116. PubMed ID: 36191308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
    Wilson JM; Nikooienejad A; Robins DA; Roell WC; Riesmeyer JS; Haupt A; Duffin KL; Taskinen MR; Ruotolo G
    Diabetes Obes Metab; 2020 Dec; 22(12):2451-2459. PubMed ID: 33462955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural determinants of dual incretin receptor agonism by tirzepatide.
    Sun B; Willard FS; Feng D; Alsina-Fernandez J; Chen Q; Vieth M; Ho JD; Showalter AD; Stutsman C; Ding L; Suter TM; Dunbar JD; Carpenter JW; Mohammed FA; Aihara E; Brown RA; Bueno AB; Emmerson PJ; Moyers JS; Kobilka TS; Coghlan MP; Kobilka BK; Sloop KW
    Proc Natl Acad Sci U S A; 2022 Mar; 119(13):e2116506119. PubMed ID: 35333651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S; Quinlan T; Landry J; Martin J; Loghin C
    Clin Pharmacokinet; 2021 Aug; 60(8):1049-1059. PubMed ID: 33778934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tirzepatide highly effective for weight loss.
    Tysoe O
    Nat Rev Endocrinol; 2022 Sep; 18(9):520. PubMed ID: 35760842
    [No Abstract]   [Full Text] [Related]  

  • 18. Tirzepatide to treat obesity: phase III results.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2022 Aug; 19(8):488. PubMed ID: 35773392
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of tirzepatide on prediabetics and blood pressure with implications for future research.
    Seetharaman R
    J Basic Clin Physiol Pharmacol; 2023 Mar; 34(2):243-244. PubMed ID: 36607902
    [No Abstract]   [Full Text] [Related]  

  • 20. Tirzepatide and the new era of twincretins for diabetes.
    Tan TM; Khoo B
    Lancet; 2021 Jul; 398(10295):95-97. PubMed ID: 34186023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.